Endonovo Therapeutics (ENDV) Invested Capital (2016 - 2023)
Endonovo Therapeutics has reported Invested Capital over the past 13 years, most recently at -$17.1 million for Q3 2023.
- Quarterly results put Invested Capital at -$17.1 million for Q3 2023, down 18.7% from a year ago — trailing twelve months through Sep 2023 was -$17.1 million (down 18.7% YoY), and the annual figure for FY2022 was -$14.8 million, down 20.19%.
- Invested Capital for Q3 2023 was -$17.1 million at Endonovo Therapeutics, down from -$16.5 million in the prior quarter.
- Over the last five years, Invested Capital for ENDV hit a ceiling of -$7.8 million in Q1 2019 and a floor of -$17.1 million in Q3 2023.
- Median Invested Capital over the past 5 years was -$11.1 million (2021), compared with a mean of -$11.7 million.
- Biggest five-year swings in Invested Capital: plummeted 486.93% in 2019 and later grew 2.04% in 2020.
- Endonovo Therapeutics' Invested Capital stood at -$9.9 million in 2019, then fell by 2.7% to -$10.2 million in 2020, then fell by 21.24% to -$12.3 million in 2021, then decreased by 20.19% to -$14.8 million in 2022, then decreased by 15.09% to -$17.1 million in 2023.
- The last three reported values for Invested Capital were -$17.1 million (Q3 2023), -$16.5 million (Q2 2023), and -$15.0 million (Q1 2023) per Business Quant data.